
Jonathan Vogelgsang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2072684/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Detection and quantification of Aβâ^'3–40 (APP669â€₹11) in cerebrospinal fluid. Journal of Neurochemistry, 2022, 160, 578-589.	3.9	6
2	Novel Exosome Biomarker Candidates for Alzheimer's Disease Unravelled Through Mass Spectrometry Analysis. Molecular Neurobiology, 2022, 59, 2838-2854.	4.0	13
3	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
4	Identification of risk factors for delirium, cognitive decline, and dementia after cardiac surgery (FINDERI—find delirium risk factors): a study protocol of a prospective observational study. BMC Cardiovascular Disorders, 2022, 22, .	1.7	4
5	Exosomal Aβ-Binding Proteins Identified by "In Silico―Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimer´s Disease. International Journal of Molecular Sciences, 2021, 22, 3933.	4.1	12
6	Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 94.	6.2	12
7	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
8	Current clinical practice of electroconvulsive therapy and repetitive transcranial magnetic stimulation in psychiatry, a German sample. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 181-190.	3.2	4
9	Prevalence of affective disorders and dementia in inflammatory polyarthropathies. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 247-252.	3.2	0
10	Nuclear medical imaging as part of dementia diagnostics in psychiatric day-care clinics and inpatient care settings. Aging Clinical and Experimental Research, 2020, 32, 809-815.	2.9	0
11	Development and Technical Validation of an Immunoassay for the Detection of APP669–711 (Aβâ^3–40) in Biological Samples. International Journal of Molecular Sciences, 2020, 21, 6564.	4.1	12
12	Pre-Analytical Sampling and Storage Conditions of Amyloid-β Peptides in Venous and Capillary Blood. Journal of Alzheimer's Disease, 2020, 78, 529-535.	2.6	11
13	Potential of FTIR Spectroscopy Applied to Exosomes for Alzheimer's Disease Discrimination: A Pilot Study. Journal of Alzheimer's Disease, 2020, 74, 391-405.	2.6	27
14	Higher Level of Mismatch in <i>APOE</i> ε 4 Carriers for Amyloid-Beta Peptide Alzheimer's Disease Biomarkers in Cerebrospinal Fluid. ASN Neuro, 2019, 11, 175909141984552.	2.7	10
15	Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits. Clinica Chimica Acta, 2019, 492, 62-68.	1.1	20
16	Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease. Journal of Neural Transmission, 2019, 126, 339-348.	2.8	16
17	Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease. Experimental Brain Research, 2018, 236, 1241-1250.	1.5	28
18	A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 121.	6.2	39

#	Article	IF	CITATIONS
19	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 87.	6.2	13
20	Cardiovascular and metabolic comorbidities in patients with Alzheimer's disease and vascular dementia compared to a psychiatric control cohort. Psychogeriatrics, 2018, 18, 393-401.	1.2	13
21	Reproducibility of Alzheimer's Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions. Journal of Alzheimer's Disease, 2018, 62, 203-212.	2.6	14